Most Recent
The state of Western Australia has been left with a $2 million legal bill for defending a defamation action by billionaire Clive Palmer and advancing cross-claims on behalf of premier Mark McGowan, which a judge blasted as "a futile exercise".
The founder of investment group Mayfair 101 must foot half his costs of a successful appeal of a 20-year ban on fund raising because of the many "spurious" grounds of appeal he pressed.
The competition regulator has detailed "significant" concerns with Cochlear’s proposed acquisition of Oticon Medical, saying Thursday a tie-up would cut to three the number of cochlear implant suppliers in Australia.
The ACCC has secured its first enforcement outcome related solely to the concerted practices provisions of the competition law, in a case that shows the watchdog is willing to take action to prevent what it sees as anti-competitive practices that include sharing sensitive price information, write Gilbert + Tobin's Jeremy Jose, Sarah Lynch and Katie Latham.
Former CEO of failed van Eyk Research has been sentenced to 15 months' imprisonment after admitting he breached his duties as director of a subsidiary to dishonestly retain control of the company.
The consumer regulator has taken Dell Australia to court for allegedly making misleading statements about the price of add-on monitors that could be purchased with Dell computers during the height of the COVID-19 pandemic.
A joint court application by ASIC and NSW Fair Trading calls for special purpose liquidators to claw back money from funeral insurer Youpla over concerns about the current liquidator's relationship with the failed company's former lawyer.
Teleco contractor BSA, which resolved a class action by its workforce for $20 million, won't be recouping the costs of legal action to exclude a $13 million capital raising from the settlement.
White & Case has expanded its competition practice in Australia with the recruitment of a former Allen & Overy lawyer to the firm's Sydney office.
Two law firms that filed competing class actions against regenerative medicine company Mesoblast for allegedly misleading shareholders about its Remestemcel-L treatment for COVID-19 complications have agreed to join forces and sidestep a beauty parade.